Phase I & II Human Clinical Trials

Since 2019 ArtemiLife™️ has collaborated with the University of Kentucky Markey Cancer Center to conduct human trials using ArtemiCafé™️ Decaf.

Milestones and Findings

  • Investigational New Drug (IND) application obtained from FDA

  • 2021 - 2024: Phase I clinical trial, stage II-IV ovarian cancer patients post treatment

  • ArtemiCafé™️ Decaf administered up to four times a day is safe and is the recommended dose for all future studies

  • Limited to no side effects (none exceeded grade 1)

  • 2023 - Ongoing: Phase II clinical trial in prostate cancer patients with rising PSA level

Next Steps Upon Funding:

  • 12 Additional Phase II cancer trials

  • A five-year cancer preventative trial